Payor Guidance Follow Up: Execution and Real World Challenges

Michael S. Labson, Partner, Covington & Burling LLP

Paul Savidge, US General Counsel, Spark Therapeutics and Co-Chair, Advertising & Promotion for Medical Products Conference Planning Committee

Jay Weaver, Associate Vice President, Pharmacy at Blue Cross and Blue Shield of Illinois, Montana, New Mexico, Oklahoma & Texas

Moderated by Wayne Pines, President, Regulatory Services and Healthcare, APCO Worldwide
Payor Guidance Follow Up: Execution and Real World Challenges

Michael S. Labson
October 17, 2019
Background
Evolving Rules for Communications to Payors

- FDAMA sec. 114 (1997)
- 21st C. Cures sec. 3037 (2016)
- FDA Guidance, Drug & Device Mfr. Communications w/ Payors, Formulary Committees and Similar Entities (Draft 2017) (Final 2018)

Codified at FDCA sec. 502(a)
Healthcare Economic Information to Payors on Approved Products

Healthcare economic information (HCEI) …

… to payors, formulary committees, and similar entities …

… related to an approved indication …

supported by competent and reliable scientific evidence (CARSE)
Unapproved Products and Uses

- Product information (e.g., drug class)
- Indication sought, including endpoints and populations studied
- “Factual presentations of results from studies, including clinical studies … (i.e., no characterizations or conclusions should be made regarding the safety or effectiveness of the unapproved product or unapproved use)”
- Anticipated timeline for FDA action
- Product pricing information
- Patient utilization projections
- Product-related programs/services (e.g., patient support programs)
Question & Challenges in Practice
1) Scope of eligible audience  
   a) What entities are “similar” to payors and formulary committees?  
   b) Are advisors to P&T decision-makers eligible?  
   c) How to document eligibility?  
2) Scope of pre-approval communications  
   a) Who from a company may communicate pre-approval information?  
   b) May HCEI be communicated pre-approval?  
3) What is an HCEI analysis?  
4) What is CARSE (and how does it relate to substantial evidence, SASS, truthful/non-misleading)?  
5) How to treat communications around value-based contracts?  
6) What are standards for communicating HCEI to other (non-payors) audiences?
Thank You!

Michael S. Labson
Covington & Burling LLP
(202) 662-5220
mlabson@cov.com
Disclaimer

The presentations and statements in this program are solely those of the individual attorneys, and are not intended to be construed as presentations or statements of Covington & Burling LLP or of any of Covington’s clients. In addition, the presentations and statements in this program are not intended to be legal advice.
The Payor Guidance in Action: The Experience of Spark Therapeutics

Paul Savidge
US General Counsel
Spark Therapeutics
October 17, 2019
The views and opinions expressed are not intended as legal advice on any particular issue.

They reflect an interpretation of FDA guidance as applied to a specific experience.

Presentation is for educational purposes only and is not intended to promote the use of any product.
“Payors have indicated that due, in part, to their need to, in some situations, plan for and make coverage and reimbursement decisions far in advance of the effective date of such decisions, they are ...interested in receiving information ...about medicinal products that are not yet approved by FDA for any use and about unapproved uses of approved medicinal products.”
Gene therapy represents an entirely new approach to health care

If approved, voretigene neparvovec would be the very first gene therapy for a genetic disease in the United States

• *Would treat a disease for which there was no medical treatment*

Very low levels of understanding among payors of gene therapy or how it would work

Very low levels of understanding among payors of the clinical development program supporting voretigene neparvovec

Very low levels of understanding among payors of how they might value the benefit of this investigational product for purposes of reimbursement

Because of the progressive nature of the genetic disease (a form of blindness), it was critical that the therapy be available to appropriate patients through payors as quickly as possible post-approval.
21 CFR 312.7(a) limited how firms could communicate information regarding investigational new drugs, including to payors

(a) Promotion of an investigational new drug. A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug. This provision is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media. Rather, its intent is to restrict promotional claims of safety or effectiveness of the drug for a use for which it is under investigation and to preclude commercialization of the drug before it is approved for commercial distribution.

Pre-guidance, firms would primarily rely on the unprompted/unsolicited questions from payors about investigational therapies
“When the following types of information about unapproved products or unapproved uses provided by firms to payors are unbiased, factual, accurate and non-misleading… FDA does not intend to object … [to] such communications as evidence of a new intended use [and] does not intend to enforce any applicable postmarketing submission requirements for these materials.”
Types of information firms may communicate to payors about investigational products or uses:

- **Product information** (e.g., drug class, device description and features)
  Indication sought: study protocol, endpoints and patient population being studied
  Factual presentation of results (i.e., no safety/efficacy characterization or conclusions)

- **Product-related programs or services** (e.g., patient support programs)

- **Anticipated timeline for possible FDA approval/clearance**

- **Pricing information**

- **Patient utilization projections** (epidemiology data projection on incidence and prevalence)
Investigational voretigene neparvorec

A potential gene therapy treatment from Spark Therapeutics

Voretigene neparvorec is under investigation and its safety and effectiveness have not been established.
Spark Therapeutics is a fully integrated gene therapy company
We don’t follow footsteps—we create the path

Our investigational gene therapy approach uses a viral vector platform with the goal of delivering functional genetic material into cells, potentially altering the course of disease.

Investigational voretigene neaparvovec (IVN) has orphan designations in the United States and European Union, as well as breakthrough therapy designation in the United States.
Spark Therapeutics is a fully integrated gene therapy company

We don't follow footsteps—we create the path

Our most advanced product candidate is investigational voretigene neparvovec (IVN), a potential therapy for patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy.

Investigational voretigene neparvovec (IVN) has orphan designations in the United States and European Union, as well as breakthrough therapy designation in the United States.
Biallelic RPE65-mediated IRD

RPE65 gene encodes the RPE65 protein, a critical component in the visual cycle

- The RPE65 protein affects the function of both rods and cones, but its greatest initial impact is rod-mediated
- The RPE65 protein aids in converting light that enters the eye into electrical signals that go to the brain
- Mutations to the RPE65 gene impact the visual cycle
- RPE65 mutations disturb function of the RPE65 protein, leading to photoreceptor degeneration and progressive vision loss
- In severe cases, RPE65 mutations manifest as visual impairment at birth

References
Approaches to treating genetic disease

The goal of gene therapy research is to employ new genetic material to address a defective genetic sequence\(^1\)

Gene therapy approaches may:

**Introduce**

a new gene into the body to help fight disease\(^1\)

Gene therapies are being investigated to determine whether they can help the body compensate for a disease-causing copy of a gene and potentially alter the effect of the disease\(^2-4\)
The development of IVN


IVN has completed the randomized, controlled, pivotal portion of the phase 3 clinical trial for potential treatment of RPE65-mediated IRD.

Voretigene neparvovec is under investigation and its safety and effectiveness have not been established.
Phase 3 clinical trial design\(^1\)

The intent-to-treat (ITT) population included all randomized subjects and the modified ITT (mITT) population included all randomized subjects who did not withdraw, or were not withdrawn, prior to any of the following people knowing the treatment assignment: the subject, parent, principal investigator, or medical monitor.

MLMT, multi-luminance mobility testing; OCT, optical coherence tomography; vo, vector genomes.

Reference
Phase 3 trial endpoints

**Primary Endpoint**

Bilateral multi-luminance mobility test

Measures functional vision at light levels encountered during typical activities of daily living.

- Refers to participants’ ability (speed and accuracy) to navigate a mobility course under a variety of specified light levels.

- While taking the test, each subject follows arrows on the floor, steps over objects in their path, and exits the course.

- Light levels are measured by lux.

References


### Overview of phase 3 one-year results: efficacy endpoints (ITT)\(^1,2\)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Measurement</th>
<th>Difference (95% CI) Intervention-control</th>
<th>Statistical significance (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary endpoint</strong></td>
<td>MLMT performance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilateral, change score</td>
<td></td>
<td>1.6 (0.72, 2.41)</td>
<td>p = 0.001</td>
</tr>
<tr>
<td><strong>Secondary endpoints</strong></td>
<td>FST testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocular, averaged over both eyes, log10 (cd.s/m(^2))</td>
<td></td>
<td>-2.11 (-3.19, -1.04)</td>
<td>p &lt; 0.001</td>
</tr>
<tr>
<td><strong>MLMT performance</strong></td>
<td>Assigned first eye, change score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocular, averaged over both eyes, logMAR (Holladay)</td>
<td></td>
<td>1.7 (0.89, 2.52)</td>
<td>p = 0.001</td>
</tr>
<tr>
<td><strong>Visual acuity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monocular, averaged over both eyes, logMAR (Holladay)</td>
<td></td>
<td>-0.16 (-0.41, 0.08)</td>
<td>p = 0.17</td>
</tr>
<tr>
<td><strong>Additional endpoint</strong></td>
<td>Visual field</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goldman III4e sum total degrees, monocular, averaged over both eyes</td>
<td></td>
<td>378.7 (145.5, 612.0)</td>
<td>Nominal p = 0.006</td>
</tr>
<tr>
<td>Humphrey macula threshold, dB, monocular, averaged over both eyes</td>
<td></td>
<td>7.9 (3.5, 12.2)</td>
<td>Nominal p &lt; 0.001</td>
</tr>
</tbody>
</table>

\(\text{dB, decibel; FST, full-field light sensitivity threshold; ITT, intent-to-treat; MLMT, multi-luminance mobility test.}
\(\text{\^LogMAR assigned using scale adapted from Holladay et al.}
\(\text{\*Voretigene nebavunec is under investigation and its safety and effectiveness have not been established.}\)
Phase 3 safety overview years 1 and 2

No product-related serious adverse events or deleterious immune responses

- All subjects experienced at least one treatment emergent adverse event (TEAE)
- No TEAEs were considered related to study drug

Summary of TEAEs reported in more than one subject (safety)

<table>
<thead>
<tr>
<th>MedDRA system organ class/preferred term</th>
<th>Intervention (N=20)</th>
<th>Control (N=9)</th>
<th>Overall (N=29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal disorders</td>
<td>12 (60%)</td>
<td>3 (33%)</td>
<td>15 (52%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>8 (40%)</td>
<td>2 (22%)</td>
<td>10 (34%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>6 (30%)</td>
<td>1 (11%)</td>
<td>7 (24%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2 (10%)</td>
<td>1 (11%)</td>
<td>3 (10%)</td>
</tr>
<tr>
<td>Upper abdominal pain</td>
<td>2 (10%)</td>
<td>0</td>
<td>2 (7%)</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>10 (50%)</td>
<td>3 (33%)</td>
<td>13 (45%)</td>
</tr>
<tr>
<td>Headache</td>
<td>7 (35%)</td>
<td>2 (22%)</td>
<td>9 (31%)</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>10 (50%)</td>
<td>1 (11%)</td>
<td>11 (38%)</td>
</tr>
<tr>
<td>Cataract</td>
<td>3 (15%)</td>
<td>0</td>
<td>3 (10%)</td>
</tr>
<tr>
<td>Eye inflammation</td>
<td>2 (10%)</td>
<td>0</td>
<td>2 (7%)</td>
</tr>
<tr>
<td>Retinal tear</td>
<td>2 (10%)</td>
<td>0</td>
<td>2 (7%)</td>
</tr>
</tbody>
</table>

For system organ class (SOC), N (%) includes any subject with an AE in that SOC; listed preferred terms (PTs) only include those experienced by more than one subject overall.

Voretigene cenevovec is under investigation and its safety and effectiveness have not been established.
Perspectives on Implementing the Guidance

• Novel considerations by firms engaging in these communications: Who should deliver? Who else can be present? Who should create? Who should review and approve?

• Critical for training of representatives delivering information to emphasize key differences from traditional product promotion (e.g., no characterization or conclusions of efficacy/safety, prominent mention of investigational status)

• Must resist temptation for firms to answer “So what?” question by payor after hearing all the investigational data

• Providing recommended data and status updates: mode of dissemination, optional vs necessary updates, positive and negative developments

• Discontinue use of these communications upon FDA approval
Perspectives on Implementing the Guidance (continued)

• Guidance has been positively received by payors, especially for investigational products with unique coverage or reimbursement considerations.

• May be particularly useful for companies introducing novel therapies or first in class therapies.

• Payors appreciate that information is factual and objective; not promotional in tone or intent.

• Payors receive information that previously would require unsolicited inquiries via Medical Information, through AMCP dossier submissions or at medical/scientific conferences.
Payor Perspective on 2018 Promotional Guidance

S. Jay Weaver, PharmD, MPH
AVP, Pharmaceutical Care Strategy
HCSC
Pharmacy and Therapeutics Committee (P&T)
- Clinical committee assesses clinical merits and place-in-care
- Traditionally used published studies, labeling/PI, clinical guidelines

Contracting/Business Committee
- Evaluated placement of products relative to P&T mandate
- Traditionally use home-grown HCEI models, published evaluations and limited manufacturer models for financial considerations
- ICER and NICE evaluations emerging as additional data points
Traditional payor budgeting process and tools

HEOR models (HCEI)
* Budget-impact models
* Epidemiology data
* Enrollment projections

Pipeline evaluation and projection
* Pink Sheet
* FDA
* Investor calls
* Pricing (best guess)
Challenges

- Assumption variability
- Timeliness of information
- Costliness of research
- Price of publications
- Lack of outcomes data (surrogate endpoint only)
- Small populations for orphan products
Key points of “The Guidance”

* Changed from “substantial evidence” (typically two randomized controlled trials) to “competent and reliable scientific evidence”, if these claims were made to “formulary committees and similar entities” and “directly-related to approved indications.”

* Allows for sharing information regarding unapproved products to payors as long as that information is “unbiased, factual, accurate, and non-misleading, and are presented with statements regarding:
  * Approval status
  * Stage of product development
  * Material aspects of study design (where appropriate)
  * Approved indication if discussing indication for which it is not approved
Wins

* Allows payors to see more appropriate models to address financial questions
* Earlier budget impact evaluations with less plan overhead

Concerns

* Declining evidentiary standards requiring more vigilance
* Unclear if changing evidentiary standards for manufacturers translates to pricing improvements
Life after “The Guidance” around the payor community

* Increased offers to discuss pipeline/investigational agents
* Expanded discussions of HCEI models
* Offers to meet to discuss agents prior to launch
* Payors reconfiguring evaluation techniques to include PROs
* Payors contemplating how to leverage their data-sets in partnership with industry
Questions
Payor Guidance Follow Up: Execution and Real World Challenges

Michael S. Labson, Partner, Covington & Burling LLP
Paul Savidge, US General Counsel, Spark Therapeutics and Co-Chair, Advertising & Promotion for Medical Products Conference Planning Committee
Jay Weaver, Associate Vice President, Pharmacy at Blue Cross and Blue Shield of Illinois, Montana, New Mexico, Oklahoma & Texas

Moderated by Wayne Pines, President, Regulatory Services and Healthcare, APCO Worldwide